Navigation Links
Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free
Date:9/19/2013

EAST HANOVER, N.J., Sept. 19, 2013 /PRNewswire/ -- Novartis commemorates World CML Day by announcing the latest milestone in its unique clinical trial program evaluating the potential for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) to maintain undetectable levels of disease after stopping drug therapy – a concept called treatment-free remission. More than 100 study sites are now enrolling patients to the trial program.

Since 2008, organizations around the world have recognized World CML Day1. The date, September 22 or 9/22, was chosen to symbolically represent the genetic material that is associated with CML – the missing section from chromosome 22 shifts to chromosome 9 and vice versa, in a phenomenon called "translocation2." Known as the Philadelphia chromosome, this genetic mutation is present in about 95% of CML patients3.

"As a leader in CML, Novartis is proud to support World CML Day through our continued dedication to ongoing research in this disease," said Herve Hoppenot, President, Novartis Oncology. "We are now exploring if the disease can be treated to a point where drug therapy is no longer needed, representing the next step in what may be possible for patients living with Ph+ CML."

Over the past decades, Novartis research in Ph+ CML has helped transform the disease from a fatal diagnosis to a chronic condition for many patients. Today, the company continues its long-standing commitment to the global CML community. The Novartis treatment-free remission clinical trial program[*] includes eight studies that are now underway and actively enrolling Ph+ CML patients in more than 100 global sites across 40 countries.

_______________________________________
[*] In the Novartis treatment-free remission
'/>"/>

SOURCE Novartis
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
2. Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
3. Leaders from Pfizer, Novartis and J&J Challenge Industry to Disrupt R&D
4. Novartis launches the Cancer Cell Line Encyclopedia to catalog worlds cancer cell lines
5. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
6. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
7. Spanish researchers writing in cell describe the 9 hallmarks of aging
8. Discovery of gene mutation causing Sturge-Weber syndrome, port-wine stain birthmarks offers new hope
9. Nutra Pharma Patent and Trademarks Published in India
10. Spider Bully for Less: My Cleaning Products Marks Down the Spray for its Christmas Special
11. My Cleaning Products Marks Down Its Bed Bug Bully Price by 20%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... May 21, 2015 Tunnell Consulting, ... the firm as senior statistician and Principal, a position ... experience in the management and analysis of complex and ... chemical industries. , “We’re delighted to have Julia join ... data analytics,” said Dr. Philippe Cini, Group Vice President ...
(Date:5/20/2015)... MECHANICSBURG, Pa. , May 20, 2015 /PRNewswire/ ... announced that the Federal Trade Commission granted early ... (HSR) Antitrust Improvements Act of 1976, as amended, ... by MJ Acquisition Corporation, a joint venture that ... XII, L.P. As previously announced, MJ ...
(Date:5/20/2015)... 20, 2015  Haemonetics Corporation (NYSE: HAE ) ... CEO, will present at The Jefferies 2015 Global Healthcare ... June 1 st , 2015 at 8:30am Eastern time.  ... presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated to ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Surface Logix today announced positive,results in ... SLx-4090 in,dyslipidemia (high cholesterol and triglyceride levels ... 2a study in 24,patients with dyslipidemia demonstrated ... triglycerides and LDL-cholesterol,and was well tolerated. The ...
... Edwards Lifesciences,Corporation (NYSE: EW ), the world leader ... has received conditional approval from the U.S.,Food and Drug ... pivotal,clinical trial of the Edwards SAPIEN transcatheter aortic heart ... transapical,delivery system to the trial, and also granted permission ...
... ) consolidated net earnings for the quarter ended December ... diluted share compared,with $18.7 million or $.47 per diluted ... six months ended December 31, 2007, Techne,s consolidated,net earnings ... share,compared with $38.3 million or $0.97 per diluted share ...
Cached Biology Technology:Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial 2Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial 3Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial 4Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve 2Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve 3Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 2Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 3Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 4Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 5Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 6Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008 7
(Date:4/27/2015)... 27, 2015  For more than four decades, AUVSI,s ... been the premier worldwide event for the unmanned land, ... must-attend event for any local, national, or trade news ... commercial markets and current applications of unmanned technologies. The ... projected $48 billion industry, and how it will soon ...
(Date:4/20/2015)... , April 20, 2015 ...   Glenbeigh Records Management (GRM), Ireland,s ... with Dubai Islamic Bank. Having built up an impressive track ... now a leading player within the records management sector in ... expects to double is GCC staffbase and employ a further ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... CLEMSON The National Science Foundation (NSF) has awarded ... Engineering (CBIOE) at Clemson University for the development of ... causes, progression and treatment of breast cancer. The ... based on inkjet printing and will allow the creation ...
... Over the last forty years, Shigetada Nakanishi has unraveled ... the human nervous system. His work has created ... Today at 2.30 pm he will receive the Gruber ... Diego. In the 2007 Gruber Lecture he will ...
... the Journal of Proteome Research, authored by researchers ... Rosetta Inpharmatics LLC, CXR Biosciences Ltd, the Cancer ... and enhanced analytic power of the combination of ... microarray analysis methods of Genomatix Software GmbH., The ...
Cached Biology News:Breast cancer research and inkjet tissue printing get NSF boost 2Shigetada Nakanishi receives $500,000 Gruber Neuroscience Prize 2
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
... Thermo's Wellwash AC is the easiest ... and is provided with liquid level ... bottles. The integrated orbital shaker and ... excellent washing performance. The big bottle ...
Biology Products: